ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in ProPhase Labs, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 2
- −14 vs. Q4 2025
- Shares held
- 20
- −154.3K (−100.0%) vs. Q4 2025
- Total value
- $2
- −$69.1K (−100.0%) vs. Q4 2025
- New holders
- 0
- 1 more added
- Sold out
- 14
- 1 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PRPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $2 |
| Q1 2026 | 2 | $2 |
| Q4 2025 | 17 | $92.9K |
| Q3 2025 | 29 | $1.36M |
| Q2 2025 | 33 | $1.05M |
| Q1 2025 | 37 | $2.02M |
| Q4 2024 | 30 | $1.91M |
| Q3 2024 | 27 | $4.23M |
| Q2 2024 | 29 | $7.27M |
| Q1 2024 | 32 | $11.0M |
| Q4 2023 | 27 | $7.63M |
| Q3 2023 | 35 | $8.56M |
| Q2 2023 | 45 | $15.8M |
| Q1 2023 | 39 | $18.6M |
| Q4 2022 | 51 | $26.7M |
| Q3 2022 | 43 | $30.3M |
| Q2 2022 | 39 | $24.9M |
| Q1 2022 | 22 | $10.8M |
| Q4 2021 | 25 | $10.8M |
| Q3 2021 | 21 | $8.56M |
| Q2 2021 | 23 | $9.95M |
| Q1 2021 | 29 | $9.58M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding ProPhase Labs, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CoreCap Advisors, LLC | 10 | $1 | 0.00% | −710−98.6% | Reduced |
| Farther Finance Advisors, LLC | 10 | $1 | 0.00% | +1+11.1% | Added |
| Sykon Capital LLC | 0 | $0 | 0.00% | −64,478−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −21,952−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −18,839−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −16,262−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −7,431−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,056−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −919−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −177−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −163−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −126−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −114−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |